Corona Virus How To Treat

[David PS]

Low blood viscosity seems to be important for surviving covid and the clot shots.

The Detrimental Role of Elevated Blood Viscosity in Patients With COVID-19 | Sloop | Journal of Cardiology and Therapy

96.126.98.199

Change of blood viscosity after COVID-19 vaccination: estimation for persons with underlying metabolic syndrome

The COVID-19 vaccine is a new vaccine aiming at control of COVID-19 pandemic. This new vaccine is useful for pandemic management, however, an important consideration is on its safety. Thrombosis is a problem might occur after COVID-19 vaccination and ...

www.ncbi.nlm.nih.gov

Association of Blood Viscosity With Mortality Among Patients Hospitalized With COVID-19

Coronavirus disease-2019 (COVID-19) is characterized by a dysfunctional immune response and abnormal blood rheology that contribute to endothelial dysfunction and thrombotic complications. Whole blood viscosity (WBV) is a clinically validated measure ...

www.ncbi.nlm.nih.gov

Myocarditis and Thrombosis Following Immunization for COVID-19 Are Caused By Elevated Blood Viscosity and May Be Prevented By Optimal Oral Hydration

From the Oligonucleotide purUUpurU to Cytokine Storm, Elevated Blood Viscosity, and Complications of Coronavirus Disease 2019

Background Coronavirus disease 2019 (COVID-19) can be associated with pathologic inflammation. The authors hypothesize that a high copy number of a purine-uridine-rich nucleotide motif is present in the genome of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and hyperactivates...

www.cureus.com

COVID-19 Demonstrates That Inflammation Is a Hyperviscous State

Many of the complications of severe coronavirus disease-2019 (COVID-19) are caused by blood hyperviscosity driven by marked hyperfibrinogenemia. This results in a distinctive hyperviscosity syndrome which affects areas of high and low shear. A change in blood viscosity causes a threefold inverse...

www.cureus.com

Changes in the Blood Viscosity in Patients With SARS-CoV-2 Infection

Coronavirus disease 2019 (COVID-19) is caused by a novel virus known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). SARS-CoV-2-induced hyperinflammation together with alteration of plasma proteins, erythrocyte deformability, and platelet ...

www.ncbi.nlm.nih.gov

Blood hyperviscosity in acute and recent COVID-19 infection - IOS Press

BACKGROUND: Elevated estimated blood viscosity (EBV), derived from hematocrit and globulins, is associated with thrombotic complications, organ failure, and higher mortality in COVID-19 patients. Although informative, EBV does not account for cellula

content.iospress.com

Blood viscosity of COVID-19 patient: a preliminary report

COVID-19 is the important global problem. This new coronavirus can cause several hematological changes. Thrombosis is a problem might occur in COVID-19. In COVID-19, thrombosis might be the result of endothelial dysfunction, platelet activation, increasd ...

www.ncbi.nlm.nih.gov

 

[Zsazsa]

FXR inhibition may protect from SARS-CoV-2 infection by reducing ACE2 - Nature

Prevention of SARS-CoV-2 infection through the modulation of viral host receptors, such as ACE21, could represent a new chemoprophylactic approach for COVID-19 complementing vaccination2,3. However, the mechanisms controlling ACE2 expression remain elusive. Here, we identify the farnesoid X...

www.nature.com

Article
Published: 05 December 2022
FXR inhibition may protect from SARS-CoV-2 infection by reducing ACE2

We are providing an unedited version of this manuscript to give early access to its findings. Before final publication, the manuscript will undergo further editing. Please note there may be errors present which affect the content, and all legal disclaimers apply.

Abstract
Prevention of SARS-CoV-2 infection through the modulation of viral host receptors, such as ACE21, could represent a new chemoprophylactic approach for COVID-19 complementing vaccination2,3. However, the mechanisms controlling ACE2 expression remain elusive. Here, we identify the farnesoid X receptor (FXR) as a direct regulator of ACE2 transcription in multiple COVID19-affected tissues, including the gastrointestinal and respiratory systems. We then use the over-the-counter compound z-guggulsterone (ZGG) and the off-patent drug ursodeoxycholic acid (UDCA) to reduce FXR signalling and downregulate ACE2 in human lung, cholangiocyte and intestinal organoids and in the corresponding tissues in mice and hamsters. We demonstrate that UDCA-mediated ACE2 downregulation reduces susceptibility to SARS-CoV-2 infection in vitro, in vivo and in human lungs and livers perfused ex situ. Furthermore, we illustrate that UDCA reduces ACE2 expression in the nasal epithelium in humans. Finally, we identify a correlation between UDCA treatment and positive clinical outcomes following SARS-CoV-2 infection using retrospective registry data, and confirm these findings in an independent validation cohort of liver transplant recipients. In conclusion, we identify a novel function of FXR in controlling ACE2 expression and provide evidence that modulation of this pathway could be beneficial for reducing SARS-CoV-2 infection, paving the road for future clinical trials.

 

[Zsazsa]

Twice-Daily Oral Zinc in the Treatment of Patients With Coronavirus Disease 2019: A Randomized Double-Blind Controlled Trial

In this randomized controlled trial, we demonstrated that zinc administered orally to hospitalized patients with COVID-19 could prevent intensive care unit admi

academic.oup.com

CORRECTED PROOF EDITOR'S CHOICE
Twice-Daily Oral Zinc in the Treatment of Patients With Coronavirus Disease 2019: A Randomized Double-Blind Controlled Trial
Published: 04 November 2022

Abstract
Background
Zinc supplementation has been considered a potential therapy for coronavirus disease 2019 (COVID-19). We aimed to examine zinc efficacy in adult patients with COVID-19 infection.

Methods
We conducted a prospective, randomized, double-blind, placebo-controlled multicenter trial. Patients who were tested positive for COVID-19 without end-organ failure were randomized to oral zinc (n = 231) or matching placebo (n = 239) for 15 days. The primary combined outcome was death due to COVID-19 or intensive care unit (ICU) admission ≤30 days after randomization. Secondary outcomes included length of hospital stay for inpatients and duration of COVID-19 symptoms with COVID-19–related hospitalization for outpatients.

Results
190 patients (40.4%) were ambulatory and 280 patients (59.6%) were hospitalized. Mortality at 30 days was 6.5% in the zinc group and 9.2% in the placebo group (OR: .68; 95% CI .34–1.35); ICU admission rates were, respectively, 5.2% and 11.3% (OR: .43; 95% CI .21–.87). Combined outcome was lower in the zinc group versus the placebo group (OR: .58; 95% CI .33–.99). Consistent results were observed in prespecified subgroups of patients aged <65 years, those with comorbidity, and those who needed oxygen therapy at baseline. Length of hospital stay was shorter in the zinc group versus the placebo group (difference: 3.5 days; 95% CI 2.76–4.23) in the inpatient group; duration of COVID-19 symptoms decreased with zinc treatment versus placebo in outpatients (difference: 1.9 days; 95% CI .62–2.6). No severe adverse events were observed during the study.

Conclusions
Our results showed that, in COVID-19 patients, oral zinc can decrease 30-day death, ICU admission rate and can shorten symptom duration.

Clinical Trials Registration. ClinicalTrials.gov, NCT05212480.

 

[David PS]

Cardiopulmonary and hematological effects of infrared LED photobiomodulation in the treatment of SARS-COV2

COVID-19 disease is caused by SARS-CoV-2 which can trigger acute respiratory syndrome, which presents with dense alveolar and interstitial infiltrates…

www.sciencedirect.com

A vest with an array of infrared LEDs was used for treatment of COVID-19 patients.

•Photobiomodulation with infrared LED reduced hospitalization time for COVID-19.

•Infrared LED photobiomodulation promotes improvement of cardiopulmonary functions.

•Minimized symptoms of COVID-19 patients.

•Photobiomodulation therapy can be used as an adjunct in the treatment in COVID-19.

2.7. Treatment Protocol​

The cohort of 30 patients with COVID-19 was randomly divided into two equal groups. The LED group comprised patients treated with conventional therapy (medication and physiotherapy) in conjunction with infrared LED irradiation (940 nm), and the CON (placebo) group comprised patients that underwent conventional therapy alone.

Patients from both groups received conventional treatment consisting of the antibiotics Meropenem (1-2 g) or Tazocin (40 mL/min), in conjunction with respiratory physiotherapy for bronchial hygiene with a 15 Hz oral oscillation device (OOAF, Shaker, NCS, São Paulo, Brazil). Respiratory physiotherapy of 30 min, consisting of three cycles of 10 repetitions each, with an interval of 1 min between cycles, was performed daily before wearing the LED vest, during the 7 days of treatment with LED irradiation or placebo. After that time, the two groups continued only with conventional treatment until discharged from the hospital.

3.1. Outcomes Summary​

Infrared LED photobiomodulation combined with conventional therapy outcomes:

➢Enhances the effect of the conventional therapy on COVID-19 patients, presenting a statistically significant improvement in the recovery of the vital cardiopulmonary functions: Partial Oxygen Saturation, Tidal Volume, Maximum Inspiratory Pressure, Maximum Expiratory Pressure, Respiratory Rate, Heart Rate and Systolic Blood Pressure; as well as the hematological components: Leukocytes, Segmented Neutrophils and Lymphocytes.

➢Statistically significant reduction in the time of hospitalization stays of patients.

➢The time when adventitious noises improved from the date of the patient's hospital intake is significantly reduced

➢Presents an improvement in the PSI and NLCR indices when compared to conventional therapy.

➢The power of statistical analysis of the results exceeded 80%

 

[Ras]

Low blood viscosity seems to be important for surviving covid and the clot shots.

The Detrimental Role of Elevated Blood Viscosity in Patients With COVID-19 | Sloop | Journal of Cardiology and Therapy

96.126.98.199

Change of blood viscosity after COVID-19 vaccination: estimation for persons with underlying metabolic syndrome

The COVID-19 vaccine is a new vaccine aiming at control of COVID-19 pandemic. This new vaccine is useful for pandemic management, however, an important consideration is on its safety. Thrombosis is a problem might occur after COVID-19 vaccination and ...

www.ncbi.nlm.nih.gov

Association of Blood Viscosity With Mortality Among Patients Hospitalized With COVID-19

Coronavirus disease-2019 (COVID-19) is characterized by a dysfunctional immune response and abnormal blood rheology that contribute to endothelial dysfunction and thrombotic complications. Whole blood viscosity (WBV) is a clinically validated measure ...

www.ncbi.nlm.nih.gov

Myocarditis and Thrombosis Following Immunization for COVID-19 Are Caused By Elevated Blood Viscosity and May Be Prevented By Optimal Oral Hydration

From the Oligonucleotide purUUpurU to Cytokine Storm, Elevated Blood Viscosity, and Complications of Coronavirus Disease 2019

Background Coronavirus disease 2019 (COVID-19) can be associated with pathologic inflammation. The authors hypothesize that a high copy number of a purine-uridine-rich nucleotide motif is present in the genome of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and hyperactivates...

www.cureus.com

COVID-19 Demonstrates That Inflammation Is a Hyperviscous State

Many of the complications of severe coronavirus disease-2019 (COVID-19) are caused by blood hyperviscosity driven by marked hyperfibrinogenemia. This results in a distinctive hyperviscosity syndrome which affects areas of high and low shear. A change in blood viscosity causes a threefold inverse...

www.cureus.com

Changes in the Blood Viscosity in Patients With SARS-CoV-2 Infection

Coronavirus disease 2019 (COVID-19) is caused by a novel virus known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). SARS-CoV-2-induced hyperinflammation together with alteration of plasma proteins, erythrocyte deformability, and platelet ...

www.ncbi.nlm.nih.gov

Blood hyperviscosity in acute and recent COVID-19 infection - IOS Press

BACKGROUND: Elevated estimated blood viscosity (EBV), derived from hematocrit and globulins, is associated with thrombotic complications, organ failure, and higher mortality in COVID-19 patients. Although informative, EBV does not account for cellula

content.iospress.com

Blood viscosity of COVID-19 patient: a preliminary report

COVID-19 is the important global problem. This new coronavirus can cause several hematological changes. Thrombosis is a problem might occur in COVID-19. In COVID-19, thrombosis might be the result of endothelial dysfunction, platelet activation, increasd ...

www.ncbi.nlm.nih.gov

Does that mean an optimum zeta potential would be protective?

 

[David PS]

Does that mean an optimum zeta potential would be protective?

It would appear to be helpful. But I remember reading that medical anti-coagulants are unable to dissolve the clots formed in people who got the jab. Here it is important to distinguish getting the jab and merely getting covid.

Here are some old threads about zeta potential.

Search results for query: zeta potential

raypeatforum.com

 

[Jam]

View: https://twitter.com/MACottingham/status/1611500332714184704

 

[Jam]

View: https://www.youtube.com/watch?v=ZdiUnmpOgqE

 

[David PS]

Can Lactoferrin, a Natural Mammalian Milk Protein, Assist in the Battle against COVID-19?

Notwithstanding mass vaccination against specific SARS-CoV-2 variants, there is still a demand for complementary nutritional intervention strategies to fight COVID-19. The bovine milk protein lactoferrin (LF) has attracted interest of nutraceutical, food and dairy industries for its numerous...

www.mdpi.com

Notwithstanding mass vaccination against specific SARS-CoV-2 variants, there is still a demand for complementary nutritional intervention strategies to fight COVID-19. The bovine milk protein lactoferrin (LF) has attracted interest of nutraceutical, food and dairy industries for its numerous properties—ranging from anti-viral and anti-microbial to immunological—making it a potential functional ingredient in a wide variety of food applications to maintain health. Importantly, bovine LF was found to exert anti-viral activities against several types of viruses, including certain SARS-CoV-2 variants. LF’s potential effect on COVID-19 patients has seen a rapid increase of in vitro and in vivo studies published, resulting in a model on how LF might play a role during different phases of SARS-CoV-2 infection. Aim of this narrative review is two-fold: (1) to highlight the most relevant findings concerning LF’s anti-viral, anti-microbial, iron-binding, immunomodulatory, microbiota-modulatory and intestinal barrier properties that support health of the two most affected organs in COVID-19 patients (lungs and gut), and (2) to explore the possible underlying mechanisms governing its mode of action. Thanks to its potential effects on health, bovine LF can be considered a good candidate for nutritional interventions counteracting SARS-CoV-2 infection and related COVID-19 pathogenesis.

 

[David PS]

View: https://www.youtube.com/watch?v=ZdiUnmpOgqE

A follow up video.

View: https://www.youtube.com/watch?v=BW_EtdPWmKM

 

[David PS]

View: https://www.youtube.com/watch?v=YXc9mL7xEbE

Ivermectin's Mechanism of Action Against SARS-CoV-2 Described

SHAME on the hospital systems that systematically denied patients (and their begging families) this FDA-approved, Nobel prize winning, wonder drug.

petermcculloughmd.substack.com

SARS-CoV-2 Spike Protein Induces Hemagglutination: Implications for COVID-19 Morbidities and Therapeutics and for Vaccine Adverse Effects

Experimental findings for SARS-CoV-2 related to the glycan biochemistry of coronaviruses indicate that attachments from spike protein to glycoconjugates on the surfaces of red blood cells (RBCs), other blood cells and endothelial cells are key to the infectivity and morbidity of COVID-19. To...

www.mdpi.com

 

[David PS]

View: https://twitter.com/wabbitwarrior/status/1620980845623513088

 

[Lollipop2]

View: https://twitter.com/wabbitwarrior/status/1620980845623513088

I just posted another article about it - she breaks it down well:

So THAT'S why eggs are so deviled these days!

Next thing you know, eggs farms will be on fire. Oh, wait...

open.substack.com

 

[Sean.R]

View: https://odysee.com/@FrontlineCovid19CriticalCareAlliance:c/Potential-Role-of-Magnesium-for-Long-COVID-and-Vaccine-Injury:9

 

[David PS]

Resolving Colds to Advanced COVID with Methylene Blue

orthomolecular.org

 

[Osukhan]

Resolving Colds to Advanced COVID with Methylene Blue

orthomolecular.org

great breakdown of MB

 

[David PS]

This article includes examples of studies, most prior to 2020, showing the benefits of essential nutrients and other natural products in treatment of viral disease, pneumonia, and sepsis

Millions of Avoidable Deaths from COVID-19

This article may be...

orthomolecular.activehosted.com

 

[Diogo]

Very interesting.

Everyone in my house, except for my dad, had a COVID infection this month. The only thing he does differently from us, is that he takes large quantities of cannabinoids (CBD & CBG), and around 500 mg Niacin daily.

We all had fairly prominent symptoms (fever, cough, throat ache) that lasted for days... he didn't even sneeze once.

Hey there, could you explain what the effects of CBG are, please? I felt normal for the first time after tried cannabis, which the effect increased over time so I was wondering if it was one of the smaller cannabinoids.

 

[David PS]

Here is recently published study to add to the collection.

Use of either transcranial or whole-body photobiomodulation treatments improves COVID-19 brain fog - PubMed

There is increasing recognition of post-COVID-19 sequelae involving chronic fatigue and brain fog, for which photobiomodulation (PBM) therapy has been utilized. This open-label, pilot, human clinical study examined the efficacy of two PBM devices, for example, a helmet (1070 nm) for transcranial...

pubmed.ncbi.nlm.nih.gov

 

[David PS]

One half gram daily makes a difference

Moderate Dose Bovine Colostrum Supplementation in Prevention of Upper Respiratory Tract Infections in Medical University Students: A Randomized, Triple Blind, Placebo-Controlled Trial

Colostrum supplementation has been confirmed to protect from upper respiratory tract infections (URTIs) in athletes. Our trial was designed to find out whether other young adults who have potentially been exposed to increased risk of developing URTIs can also benefit. Homogenous population of...

www.mdpi.com